AbCellera Biologics Inc. (ABCL)Healthcare | Biotechnology | Vancouver, Canada | NasdaqGS
11.35 USD
-1.05
(-8.468%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 11.37 +0.02 (0.196%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:12 a.m. EDT
The immediate outlook is driven by a powerful speculative thesis rather than current profitability. While the company is burning cash with negative revenue growth and no earnings, the price action over the last two weeks has been explosive, surging from roughly $6 to over $12. This momentum is fueled by a distinct options flow pattern: traders are buying deep out-of-the-money calls, betting on a binary event like positive clinical trial results or a major licensing deal. The recent surge in volume and the 'best week since February' headline confirm that the market is pricing in a potential re-rating based on future pipeline value, not current fundamentals. However, the long-term picture remains precarious; the stock has lost nearly three-quarters of its value over the last four years, and the business is currently generating negative free cash flow with no dividend to cushion the blow. The current price is a premium for hope, making it a high-risk, high-reward momentum play suitable only for those who believe the upcoming catalysts will validate the expensive valuation, rather than a safe long-term hold. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.268509 |
| MSTL | 0.275502 |
| AutoARIMA | 0.276591 |
| AutoETS | 0.276595 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 8.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.135 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.135 |
| Revenue per Share | 0.219 |
| Market Cap | 3,677,937,664 |
| Forward P/E | -15.87 |
| Beta | 1.19 |
| Profit Margins | -248.84% |
| Website | https://www.abcellera.com |
As of Aug. 22, 2026, 2:12 a.m. EDT: Speculators are aggressively positioning for a significant upside move in the near term. Call Open Interest (OI) is heavily concentrated at strikes above the current price (12.0 and 13.0 for August expiry), while put OI is overwhelmingly skewed toward deep out-of-the-money strikes (5.0 and 6.0), indicating a 'long gamma' bias where traders expect volatility expansion upward rather than a crash. The massive volume in OTM calls suggests a speculative bet on clinical data catalysts or partnership announcements.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0617285 |
| Address1 | 150 W 4th Avenue |
| All Time High | 71.91 |
| All Time Low | 1.891 |
| Ask | 14.51 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 7,654,690 |
| Average Daily Volume3 Month | 7,931,387 |
| Average Volume | 7,931,387 |
| Average Volume10Days | 7,654,690 |
| Beta | 1.191 |
| Bid | 8.82 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 2.924 |
| City | Vancouver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.35 |
| Current Ratio | 12.77 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 12.35 |
| Day Low | 11.261 |
| Debt To Equity | 15.135 |
| Display Name | AbCellera Biologics |
| Earnings Call Timestamp End | 1,785,963,600 |
| Earnings Call Timestamp Start | 1,785,963,600 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -199,960,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -16.991 |
| Enterprise To Revenue | 51.345 |
| Enterprise Value | 3,397,495,296 |
| Eps Current Year | -0.656 |
| Eps Forward | -0.715 |
| Eps Trailing Twelve Months | -0.54 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.747 |
| Fifty Day Average Change | 3.6030002 |
| Fifty Day Average Change Percent | 0.46508327 |
| Fifty Two Week Change Percent | 206.17285 |
| Fifty Two Week High | 12.58 |
| Fifty Two Week High Change | -1.2299995 |
| Fifty Two Week High Change Percent | -0.09777421 |
| Fifty Two Week Low | 2.745 |
| Fifty Two Week Low Change | 8.6050005 |
| Fifty Two Week Low Change Percent | 3.134791 |
| Fifty Two Week Range | 2.745 - 12.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,697,000,000 |
| Float Shares | 209,038,499 |
| Forward Eps | -0.715 |
| Forward P E | -15.874127 |
| Free Cashflow | -46,431,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 562 |
| Fullday Change | -1.05 |
| Fullday Change Percent | -8.46774 |
| Fullday Price | 11.3722 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -1.98877 |
| Gross Profits | -131,597,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21736 |
| Held Percent Institutions | 0.36681 |
| Implied Shares Outstanding | 324,047,363 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-11 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. |
| Long Name | AbCellera Biologics Inc. |
| Market | us_market |
| Market Cap | 3,677,937,664 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_280568380 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -164,656,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,013,326,590 |
| Number Of Analyst Opinions | 8 |
| Open | 12.305 |
| Operating Cashflow | -94,937,000 |
| Operating Margins | -15.500489 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 604 559 9005 |
| Post Market Change | 0.02219963 |
| Post Market Change Percent | 0.19559145 |
| Post Market Price | 11.3722 |
| Post Market Time | 1,787,961,563 |
| Previous Close | 12.4 |
| Price Eps Current Year | -17.30183 |
| Price Hint | 2 |
| Price To Book | 3.881669 |
| Price To Sales Trailing12 Months | 55.58316 |
| Profit Margins | -2.48838 |
| Quick Ratio | 11.226 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -1.05 |
| Regular Market Change Percent | -8.46774 |
| Regular Market Day High | 12.35 |
| Regular Market Day Low | 11.261 |
| Regular Market Day Range | 11.261 - 12.35 |
| Regular Market Open | 12.305 |
| Regular Market Previous Close | 12.4 |
| Regular Market Price | 11.35 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 5,837,003 |
| Return On Assets | -0.103870004 |
| Return On Equity | -0.17304 |
| Revenue Growth | -0.763 |
| Revenue Per Share | 0.219 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 324,047,363 |
| Shares Percent Shares Out | 0.1276 |
| Shares Short | 41,340,862 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 45,110,268 |
| Short Name | AbCellera Biologics Inc. |
| Short Percent Of Float | 0.1626 |
| Short Ratio | 4.78 |
| Source Interval | 15 |
| State | BC |
| Symbol | ABCL |
| Target High Price | 30.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 17.125 |
| Target Median Price | 15.0 |
| Total Cash | 540,104,000 |
| Total Cash Per Share | 1.762 |
| Total Debt | 135,616,992 |
| Total Revenue | 66,170,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.54 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.9085 |
| Two Hundred Day Average Change | 6.4415 |
| Two Hundred Day Average Change Percent | 1.3123153 |
| Type Disp | Equity |
| Volume | 5,837,003 |
| Website | https://www.abcellera.com |
| Zip | V5Y 1G6 |